Rachel L. Henson
A5063197083- Dementia and Cognitive Impairment Research
- Alzheimer's disease research and treatments
- Down syndrome and intellectual disability research
- Functional Brain Connectivity Studies
- Health, Environment, Cognitive Aging
- Frailty in Older Adults
- Chronic Disease Management Strategies
- Neuroinflammation and Neurodegeneration Mechanisms
- Advanced Neuroimaging Techniques and Applications
- Tryptophan and brain disorders
- Cancer-related cognitive impairment studies
- Statistical Methods in Clinical Trials
- Machine Learning in Healthcare
- Bioinformatics and Genomic Networks
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Medical Imaging Techniques and Applications
- Single-cell and spatial transcriptomics
- Intracerebral and Subarachnoid Hemorrhage Research
- Cerebrospinal fluid and hydrocephalus
- Statistical Methods and Inference
- Genetics and Neurodevelopmental Disorders
- Health Systems, Economic Evaluations, Quality of Life
- Paraoxonase enzyme and polymorphisms
- Cerebrovascular and genetic disorders
- S100 Proteins and Annexins
Washington University in St. Louis
2018-2024
Prevent Alzheimer’s Disease 2020
2021-2024
Hope Center for Neurological Disorders
2019-2024
University of Gothenburg
2022-2024
Boston University
2024
Sahlgrenska University Hospital
2024
Mallinckrodt (United States)
2021-2022
University of Pittsburgh
2022
Institute of Neurobiology
2022
King's College London
2022
With the emergence of Alzheimer's disease (AD) disease-modifying therapies, identifying patients who could benefit from these treatments becomes critical. In this study, we evaluated whether a precise blood test perform as well established cerebrospinal fluid (CSF) tests in detecting amyloid-β (Aβ) plaques and tau tangles. Plasma %p-tau217 (ratio phosporylated-tau217 to non-phosphorylated tau) was analyzed by mass spectrometry Swedish BioFINDER-2 cohort (n = 1,422) US Charles F. Joanne...
<h3>Background and Objectives</h3> To evaluate whether plasma biomarkers of amyloid (Aβ42/Aβ40), tau (p-tau181 p-tau231), neuroaxonal injury (neurofilament light chain [NfL]) detect brain amyloidosis consistently across racial groups. <h3>Methods</h3> Individuals enrolled in studies memory aging who self-identified as African American (AA) were matched 1:1 to non-Hispanic White (NHW) individuals by age, <i>APOE</i> ε4 carrier status, cognitive status. Each participant underwent blood CSF...
Cerebrospinal fluid (CSF) amyloid-β peptide (Aβ)42/Aβ40 and the concentration of tau phosphorylated at site 181 (p-tau181) are well-established biomarkers Alzheimer's disease (AD). The present study used mass spectrometry to measure concentrations nine five nonphosphorylated species phosphorylation occupancies (percentage phosphorylated/nonphosphorylated) ten sites. In we show that, in 750 individuals with a median age 71.2 years, CSF pT217/T217 predicted presence brain amyloid by positron...
A clock relating amyloid positron emission tomography (PET) to time was used estimate the timing of biomarker changes in sporadic Alzheimer disease (AD).
Four less well-studied but promising "emerging" cerebrospinal fluid (CSF) biomarkers are elevated in late-onset Alzheimer disease (AD): neurogranin, synaptosomal-associated protein-25 (SNAP-25), visinin-like protein 1 (VILIP-1), and chitinase-3-like (YKL-40).CSF SNAP-25, VILIP-1, YKL-40 were measured families carrying autosomal-dominant AD mutations.The four emerging CSF significantly the mutation carriers (n = 235) versus noncarriers 145). altered very early time course, approximately 15-19...
The SOMAscan assay has an advantage over immunoassay-based methods because it measures a large number of proteins in cost-effective manner. However, the performance this technology compared to routinely used immunoassay techniques needs be evaluated. We performed comparative analyses and protein measurements for five cerebrospinal fluid (CSF) associated with Alzheimer's disease (AD) neurodegeneration: NfL, Neurogranin, sTREM2, VILIP-1, SNAP-25. biomarkers measured ADNI (N = 689), Knight-ADRC...
Abstract Alzheimer’s disease biomarkers are crucial to understanding pathophysiology, aiding accurate diagnosis and identifying target treatments. Although the number of continues grow, relative utility uniqueness each is poorly understood as prior work has typically calculated serial pairwise relationships on only a handful markers at time. The present study assessed cross-sectional among 27 simultaneously determined their ability predict meaningful clinical outcomes using machine learning....
To determine whether neuronal and neuroaxonal injury, neuroinflammation, synaptic dysfunction associate with clinical course outcomes in antibody-mediated encephalitis (AME), we measured biomarkers of these processes CSF from patients presenting AME cognitively normal individuals.Biomarkers (total tau, VILIP-1) damage (neurofilament light chain [NfL]), inflammation (YKL-40), function (neurogranin, SNAP-25) were obtained 45 at the time diagnosis NMDA receptor (n = 34) or LGI1/CASPR2 11) 39...
Neurofilament light is a well-established marker of both acute and chronic neuronal damage increased in multiple neurodegenerative diseases. However, the protein not well characterized brain tissue or body fluids, it unknown what neurofilament species are detected by commercial assays whether additional exist. We developed an immunoprecipitation-mass spectrometry assay using custom antibodies targeting various domains, including Coil 1A/1B rod domain (HJ30.13), 2B (HJ30.4) tail region...
Abstract Objectives Concentrations of amyloid‐β peptides (Aβ42/Aβ40) and neurofilament light (NfL) can be measured in plasma or cerebrospinal fluid (CSF) are associated with Alzheimer’s disease brain pathology cognitive impairment. This study directly compared CSF measures Aβ42/Aβ40 NfL as predictors decline. Methods Participants were 65 years older cognitively normal at baseline least one follow‐up assessment. Analytes the following types assays: Aβ42/Aβ40, immunoprecipitation‐mass...
The immune system substantially influences age-related cognitive decline and Alzheimer's disease (AD) progression, affected by genetic environmental factors. In a Mayo Clinic Study of Aging cohort, we examined how risk factors like APOE genotype, age, sex affect inflammatory molecules AD biomarkers in cerebrospinal fluid (CSF). Among cognitively unimpaired individuals over 65 (
To evaluate for racial differences in triggering receptor expressed on myeloid cells 2 (TREM2), a key immune mediator Alzheimer disease, the levels of CSF soluble TREM2 (sTREM2), and frequency associated genetic variants were compared groups individuals who self-reported their race as African American (AA) or non-Hispanic White (NHW).Community-dwelling older research participants underwent measurement sTREM2 concentrations analyses.The primary cohort included 91 AAs 868 NHWs. lower AA with...
Abstract Introduction Continuous measures of amyloid burden as measured by positron emission tomography (PET) are being used increasingly to stage Alzheimer's disease (AD). This study examined whether cerebrospinal fluid (CSF) and plasma beta (Aβ)42/Aβ40 could predict continuous values for PET. Methods CSF Aβ42 Aβ40 were with automated immunoassays. Plasma an immunoprecipitation–mass spectrometry assay. Amyloid PET was performed Pittsburgh compound B (PiB). The relationships Aβ42/Aβ40...
Abstract By age 40 years, over 90% of adults with Down syndrome have Alzheimer’s disease pathology and most progress to dementia. Despite having few systemic vascular risk factors, individuals elevated cerebrovascular markers that track the clinical progression disease, suggesting a role is hypothesized be mediated by inflammatory factors. This study examined pathways through which small vessel contributes disease-related pathophysiology neurodegeneration in syndrome. One hundred eighty-five...
Introduction Virtually all individuals with Down syndrome (DS) will develop Alzheimer's disease (AD) pathology by age 40. Cerebrospinal fluid (CSF) biomarkers have characterized AD in cohorts of late-onset (LOAD) and autosomal-dominant (ADAD). Few studies evaluated such adults DS. Methods CSF concentrations amyloid beta (Aβ)40, Aβ42, tau, phospho-tau181 (p-tau), neurofilament light chain (NfL), soluble triggering receptor expressed on myeloid cells 2 (sTREM2), chitinase-3-like protein 1...
Biomarkers of Alzheimer disease vary between groups self-identified Black and White individuals in some studies. This study examined whether the relationships biomarkers or cognitive measures varied by racialized groups.
Abstract Limbic-predominant age-related TDP-43 encephalopathy neuropathologic change (LATE-NC), is common in elderly brains and often seen conjunction with Alzheimer’s disease (ADNC). LATE-NC typically begins the amygdala spreads to hippocampus neocortex. Whether it contributes hippocampal atrophy Down syndrome (DS) remains unexplored. We analyzed volumes neuropathological burden 12 DS cases 54 non-DS AD related neurodegenerative pathologies (ADRNP) using 7 Tesla (7T) postmortem ex vivo MRI....
Background: Neuropsychiatric symptoms (NPS) can be an early manifestation of Alzheimer’s disease (AD). However, the associations among NPS, cognition, and AD biomarkers across spectrum are unclear. Objective: We analyzed cross-sectional mediation pathways between cerebrospinal fluid (CSF) (Aβ1-42, p-tau181), cognitive function, NPS. Methods: Primary models included 781 participants from National Coordinating Center (NACC) data set who had CSF for using Lumipulse. NPS were assessed with...
Post-translational modifications (PTMs) of protein tyrosine (Tyr) residues can serve as a molecular fingerprint exposure to distinct oxidative pathways and are observed in abnormally high abundance the majority human inflammatory pathologies. Reactive oxidants generated during inflammation include hypohalous acids nitric oxide-derived oxidants, which oxidatively modify Tyr via halogenation nitration, respectively, forming 3-chloroTyr, 3-bromoTyr, 3-nitroTyr. Traditional methods for...
This study was undertaken to apply established and emerging cerebrospinal fluid (CSF) biomarkers improve diagnostic accuracy in patients with rapidly progressive dementia (RPD). Overlap clinical presentation results of tests confounds etiologic diagnosis RPD. Objective measures are needed recognize potentially treatment-responsive causes
Abstract Background Traditional plate‐based assays for cerebrospinal fluid (CSF) biomarkers have been limited by relatively high assay variance that reduces the accuracy of individual measurements. Next generation automated platforms CSF reduce variability measurements, including across sample runs. In current study, we utilized Lumipulse G1200 (Fujirebio; Malvern, PA), a fully‐automated platform to compare brain amyloid burden as determined positron emission tomography (PET) imaging. Method...
Abstract INTRODUCTION Cerebrospinal fluid (CSF) tau phosphorylation at multiple sites is associated with cortical amyloid and other pathologic changes in Alzheimer's disease. These relationships can be non‐linear. We used an artificial neural network to assess the ability of 10 different CSF predict continuous positron emission tomography (PET) values. METHODS occupancies (including pT181/T181, pT217/T217, pT231/T231 pT205/T205) were measured by mass spectrometry 346 individuals (57...
Cerebral amyloid angiopathy with related inflammation (CAA-ri) is a rare age-associated disorder characterized by an inflammatory response to in cerebral blood vessels. CAA-ri often treated corticosteroids, but treatment variable.